礼来Eli Lilly & Co. (LLY) 2009年年度报告「NYSE」.pdf

1、Reinventing InventionEli Lilly and Company 2009 Annual ReportNotice of 2010 Annual MeetingProxy StatementReinventing InventionLillys vision is to improve outcomes for individual patients.To achieve this vision,we must truly reinvent pharmaceutical innovation to under-stand better individual patients

2、 and the complex diseases they face.The fact is,while patients may share common symptoms of a disease,the molecular mechanism underlying the cause or the pro-gression of the disease can vary signifi cantly among individuals.So,to improve individual patient outcomes and ultimately develop what have b

3、ecome known as“tailored therapies,”researchers must gain a deeper understanding of the disease biology of specifi c patient groups.In 2009,as part of Lillys reorganization to transform how we operate and innovate,the company launched a new group within its discovery research and clinical investigati

4、on component called“translational science.”Translational science is motivated by Lillys patient-centric vision and will focus on research that links potential medicines to disease states in distinct patient populations.Kalpana Merchant,Ph.D.,an accomplished drug hunter who was chosen to lead this ne

5、w group of experienced and passionate scientists,describes translational science as“an exciting multidisciplinary approach that will provide scientifi c insights into disease biology in individual patient populations to become the foundation of Lillys drug discovery and development strategy.”No simp

6、le feat to be sure,but by creating a single point of coor-dination globally for translational science,this new patient-centered strategy has the potential to revolutionize Lillys discovery research and development,and more importantly,to enable the delivery of innovative medicines for the patients w